The Oral Mucosa as a Delivery Route: Why It Works

Every provider evaluating an oral dissolving peptide strip eventually arrives at the same underlying question: why would dissolving something in the mouth deliver a peptide any better than swallowing a capsule? The answer is not marketing. It is anatomy and pharmacology, and it has a substantial published basis. This article explains the oral mucosa as a delivery route, what the research establishes about why it works, and the formulation factors that determine whether it works for a given molecule.

The Tissue Itself

The oral mucosa is the lining of the mouth, and for delivery purposes the regions that matter are the sublingual tissue under the tongue and the buccal tissue inside the cheeks. These surfaces share two features that make them attractive for getting a molecule into the body: they are relatively thin and permeable in places, and they are richly supplied with blood vessels. A 2025 review in Pharmaceutics describes the oral mucosa's extensive vascularization and its direct connection to systemic circulation as the central reasons drugs delivered this way can avoid first-pass metabolism within the gastrointestinal tract and liver.¹

That last point is the entire mechanism in a sentence: a molecule absorbed through the oral mucosa drains into veins that feed directly into systemic circulation, rather than being routed first through the gut wall and the liver. This is what separates dissolving a peptide in the mouth from swallowing it.

Why Swallowing Defeats Peptides

To appreciate why the oral mucosa matters, it helps to understand what swallowing does to a peptide. A peptide taken as a capsule and swallowed has to survive stomach acid, a dense population of digestive enzymes designed to break peptides into their component amino acids, and first-pass metabolism in the liver. A 2024 review in Advances in Pharmaceutical Bulletin on the oral delivery of therapeutic peptides identifies enzymatic degradation and poor permeation across the intestinal lining as the dominant reasons systemic absorption of swallowed peptides is so low.²

This is not a minor inefficiency. The digestive tract is built to dismantle peptides, which is exactly the wrong outcome when the intact peptide is the active molecule. It is the central reason so many therapeutic peptides have historically required injection. The oral mucosa offers a route that sidesteps this gauntlet, because a peptide absorbed under the tongue never reaches the digestive tract in meaningful quantity.

What the Research Establishes About Peptides Specifically

The general case for the oral mucosa is well established, but the specific question is whether peptides, which are larger and more fragile than typical small-molecule drugs, can actually cross it. The pharmaceutical literature addresses this directly. A review in Current Pharmaceutical Biotechnology on the delivery of bioactive peptides and proteins across the buccal mucosa concluded that peptides can cross this tissue by passive diffusion, with the chief barrier being the organized lipid array in the superficial epithelial layers.³ Foundational earlier work on drug delivery via the mucous membranes of the oral cavity reached a compatible conclusion: the buccal mucosa is suitable as a delivery site and can deliver peptide drugs, with the practical ceiling set by molecular size and the availability of safe penetration enhancers.⁴

So the published position is not speculative. Peptides can cross the oral mucosa, the mechanism is understood, and the route bypasses the barriers that defeat swallowing. That is a meaningful, research-backed statement, and it is the legitimate scientific basis for the oral dissolving strip format.

The Factors That Decide Whether It Works

This is where a careful provider stops short of a blanket claim. The same literature that validates the route also names its constraints clearly, and three factors recur.

Molecular size. Smaller peptides cross the oral mucosa far more readily than large ones. As molecular weight increases, passive diffusion across the epithelium falls, and larger peptides increasingly depend on formulation help.³ A route that works well for one peptide cannot be assumed to work identically for a larger one.

Residence time. A molecule only absorbs while it is in contact with the tissue. Saliva flow and swallowing constantly clear material from the mouth, which is why the research emphasizes adhesive dosage forms such as films, gels, and patches that hold the formulation against the mucosa long enough for absorption to occur.³ This is precisely the engineering problem a dissolving strip is designed to address.

Formulation and enhancers. The route's practical ceiling depends on formulation quality and the availability of safe penetration enhancers.⁴ The active peptide alone does not determine how much crosses; the delivery system does.

The honest synthesis: for appropriately sized peptides in a formulation engineered for mucosal residence, the oral mucosa is a research-supported route to systemic circulation that bypasses the digestive barriers. That is a bounded claim, and the boundaries are where accuracy lives.

Sublingual and Buccal Are Not Identical

A finer point that providers should be ready for: the two oral-mucosal regions differ. The sublingual tissue under the tongue is generally thinner and more permeable, which tends to favor faster onset, while the buccal tissue inside the cheek is somewhat less permeable but offers a larger, more stable surface that can hold an adhesive dosage form against the mucosa for longer. The reviews that describe the oral mucosa's vascular, first-pass-bypassing route also note that the specific region and the dosage form interact to determine the practical result.¹ For a patient conversation, the takeaway is modest but accurate: where and how a formulation dissolves in the mouth is part of the engineering, not an afterthought, and it is one more reason the route is best described in mechanistic terms rather than reduced to a single absorption figure.

What This Means for a Strip Format

A well-designed oral dissolving strip is essentially an attempt to optimize all three factors at once: deliver an appropriately sized peptide, hold it against the mucosa long enough to absorb, and use a formulation engineered for dissolution and residence. None of that overrides the molecule-specific limits. A strip cannot make an oversized peptide cross efficiently, and it cannot promise a fixed bioavailability across an entire product line. The per-molecule comparisons are covered in sublingual vs injectable bioavailability, and the foundational overview is in what are oral dissolving peptides.

Practical Notes for Providers

• Lead with the mechanism, not a number. The vascular, first-pass-bypassing route is the strong, citable part of the story.¹
• Contrast it with swallowing. The reason the strip differs from a capsule is digestive degradation, which the route avoids.²
• Respect the limits. Size, residence time, and formulation set the ceiling; do not generalize one peptide's behavior to all.³⁴
• Stay in scope. Evaluate products and clinical use within your scope of practice and applicable regulations, and avoid disease and approval claims.

The Bottom Line for Practices

The oral mucosa is a legitimate, well-documented systemic delivery route. Its thin, vascular tissue drains directly into circulation and bypasses the first-pass metabolism and digestive degradation that defeat swallowed peptides, and the literature confirms that peptides can cross it by passive diffusion within the limits of size, residence time, and formulation.¹²³⁴ Providers who understand the mechanism, and its boundaries, can represent the strip format accurately rather than reaching for a single bioavailability figure that the science does not support.

The oral dissolving strips in our wholesale program use patented InstaRelease® technology by InstaMed, engineered for mucosal residence and dissolution. To evaluate the format for your practice, apply for a free wholesale account.

References

1. Bahraminejad S, Almoazen H. Sublingual and Buccal Delivery: A Historical and Scientific Prescriptive. Pharmaceutics. 2025;17(8):1073. PubMed: 40871092
2. Mehrotra S, Kalyan Bg P, Nayak PG, Joseph A, Manikkath J. Recent Progress in the Oral Delivery of Therapeutic Peptides and Proteins: Overview of Pharmaceutical Strategies to Overcome Absorption Hurdles. Adv Pharm Bull. 2024;14(1):11-33. PubMed: 38585454
3. Senel S, Kremer M, Nagy K, Squier C. Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr Pharm Biotechnol. 2001;2(2):175-186. PubMed: 11480421
4. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci. 1992;81(1):1-10. PubMed: 1619560

Disclaimer: This article is for educational purposes for healthcare providers and is not medical advice. Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Absorption varies by peptide, formulation, and individual. Providers are responsible for evaluating products and clinical use within their own scope of practice and applicable regulations.